Chemotherapy and Irreversible Electroporation (IRE) in the Treatment of Advanced Pancreatic Adenocarcinoma

Trial ID: NCT03484299

Interventional - Phase 1 - Recruiting

Compare the efficacy and tolerability of IRE in combination with either FOLFIRINOX or gemcitabine in patients with locally advanced pancreatic cancer.

Conditions

• Pancreas Cancer

Interventions

• Irreversible Electroporation (IRE)
• Gemcitabine
• FOLFIRINOX

Eligibility

Inclusion criteria

• greater than or equal to 18 years of age
• diagnosed with stage III pancreatic cancer
• tumor is measurable
• GFR \> mL/min/1.73m2
• willing and able to comply with protocol requirements
• AST/ALT \>3 times upper limit of normal
• stable surgical post-operative course as defined by operative surgeon

Exclusion criteria

• participating in another clinical trial for the treatment of cancer at the time of screening
• pregnant or currently breast feeding
• have a cardiac pacemaker or ICD implanted that cannot be deactivated during IRE procedure
• have non-removable implants with metal parts within 1 cm of the target lesion
• had a myocardial infarction within 3 months prior to enrollment

Sponsor

University of Louisville

Source: ClinicalTrials.gov

Search more clinical trials on myTomorrows